Abstract
The coronavirus disease 2019 (COVID-19) caused by novel coronavirus (SARS-CoV-2) infection has created a pandemic leading to a global struggle to cope with the sheer numbers of infected persons, many of whom require intensive care support. To date, there is no specific antivirus treatment for COVID-19. The use of convalescent plasma transfusions could be of great value in the current pandemic. Recently recovered SARS-CoV-2 patients who may be suitable donors undergo apheresis in order to obtain convalescent plasma containing high-titer antibodies, granted they meet blood donation criteria. In this review, we summarize existing literature around convalescent plasma as a therapeutic option for COVID-19. It is important to note that the appropriate timing on convalescent plasma administration and the severity of its adverse effects needs to be further studied. Convalescent plasma provides the potential to render an immediate promising treatment option while evaluating existing drugs and developing new specific vaccines and therapies.
Highlights
The coronavirus disease 2019 (COVID-19) caused by the new coronavirus infection (SARSCoV-2) has created a pandemic that has led to a global fight to cope with the large number of infected people, many of which require intensive care
The use of convalescent plasma transfusions could be of great value in the current pandemic
INSTITUTO DE INVESTIGACIÓN EN CIENCIAS BIOMÉDICAS https://alicia.concytec.gob.pe/vufind/
Summary
TERAPIA DE PLASMA CONVALECIENTE PARA PACIENTES CON COVID-19: REVISIÓN DE LA LITERATURA. Después de utilizar los criterios de exclusión y eliminar los artículos duplicados, revisamos 37 estudios. Los pacientes con SRAS-CoV-2 recuperados que pueden ser donantes adecuados se someten a aféresis para obtener plasma de convalecencia que contenga anticuerpos de alto título, siempre que cumplan los criterios de donación de sangre. Conclusión: Los beneficios y la eficacia del plasma de convalecencia superan con creces los posibles efectos secundarios, ya que no existe una terapia farmacológica o vacuna específica disponible. El uso de la terapia con plasma de convalecencia en el manejo de pacientes con diferentes niveles de gravedad de la enfermedad COVID-19 se ha convertido en un pilar de manejo en el manejo global y una opción accesible en los países en desarrollo. Palabras clave: COVID; COVID-19; SARS-CoV-2; Plasma de convalecencia; Terapia de tratamiento con plasma (fuente: DeCS BIREME)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
